Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037);Real-world study of everolimus in advanced progressive neuroendocrine tumors

Oncologist

Volumn 19, Issue 9, 2014, Pages 966-974

  Panzuto, Francesco ^a   Rinzivillo, Maria ^a   Fazio, Nicola ^b   Braud, Filippo De ^c   Luppi, Gabriele ^d   Zatelli, Maria Chiara ^e   Lugli, Francesca ^f   Tomassetti, Paola ^g   Riccardi, Ferdinando ^h   Nuzzo, Carmen ⁱ   Brizzi, Maria Pia ^j   Faggiano, Antongiulio ^k   Zaniboni, Alberto ^l   Nobili, Elisabetta ⁱ   Pastorelli, Davide ^m   Cascinu, Stefano ⁿ   Merlano, Marco ^o   Chiara, Silvana ^p   Antonuzzo, Lorenzo ^q   Funaioli, Chiara ^r   Spada, Francesca ^b   Pusceddu, Sara ^c   Fontana, Annalisa ^d   Ambrosio, Maria Rosaria ^e   Cassano, Alessandra ^f   Campana, Davide ^g   Cartenì, Giacomo ^h   Appetecchia, Marialuisa ^g   Berruti, Alfredo ^s   Colao, Annamaria ^k   Falconi, Massimo ⁿ   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^j SAN LUIGI GONZAGA HOSPITAL   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l Fondazione Poliambulanza   (Italy)

^m VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁿ UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^o S CROCE E CARLE HOSPITAL   (Italy)

^p UNIVERSITY OF GENOA   (Italy)

^q CAREGGI UNIVERSITY HOSPITAL   (Italy)

^r OSPEDALE NIGUARDA CA GRANDA   (Italy)

^s SPEDALI CIVILI   (Italy)

more..

Author keywords

Carcinoids; Compassionate use; Everolimus; Neuroendocrine tumors; Pancreatic endocrine tumors; Prognosis

Indexed keywords

EVEROLIMUS; OCTREOTIDE; RAPAMYCIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOID TUMOR; CLASSIFICATION; COMPASSIONATE USE; DISEASE FREE SURVIVAL; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY;

AGED; CARCINOID TUMOR; COMPASSIONATE USE TRIALS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; SIROLIMUS;

EID: 84906976984     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0037erratum     Document Type: Erratum

References (30)

1. Fraenkel M, Kim MK, Faggiano A. etal. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012;26:691-703.
2. Pape UF, Berndt U, Müller-Nordhorn J et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-1097.
3. Jann H, Roll S, Couvelard A et al. Neuroendocrine tumors of midgut and hindgut origin: Tumornode-metastasis classification determines clinical outcome. Cancer 2011;117:3332-3341.
4. Panzuto F, Boninsegna L, Fazio N et al. Metastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with diseaseprogression. J ClinOncol 2011;29:2372-2377.
5. Panzuto F, Campana D, Fazio N et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 2012; 96:32-40.
6. Rindi G, Falconi M, Klersy C et al. TNM staging of neoplasms of the endocrine pancreas: Results from a large international cohort study. J Natl Cancer Inst 2012;104:764-777.
7. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
8. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.
9. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
10. Zatelli MC, Minoia M, Filieri C et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2010; 95:968-976.
11. Zatelli MC, Minoia M, Martini C et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010;17:719-729.
12. Bollard J, Couderc C, Blanc M et al. Antitumor effect of everolimus in preclinical models of highgrade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology 2013;97:331-340.
13. Gagliano T, Bellio M, Gentilin E et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer 2013;20: 463-475.
14. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep. cancer.gov/protocolDevelopment/electronic_ applications/docs/ctcaev3.pdf. Accessed December 31, 2013.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
16. Bosman FT, Carneiro F, Hruban RH et al. WHO Classification of Tumours of the Digestive System. 4th ed.Lyon, France: IARC Press, 2010.
17. Lauer MS, DAgostino RB Sr. The randomized registry trial—the next disruptive technology in clinical research? N Engl J Med 2013;369:1579-1581.
18. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 2010;28:69-76.
19. Lombard-Bohas C, Yao JC, Hobday TJ et al. Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: Radiant-3 subgroup analysis. J Clin Oncol 2012;30(suppl 34):224a.
20. Kamp K, Gumz B, Feelders RA et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Luoctreotate. Endocr Relat Cancer 2013;20:825-831.
21. Bergsma H, vanVliet EI, Teunissen JJ. etal. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:867-881.
22. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008; 26:4311-4318.
23. Bajetta E, Catena L, Fazio N et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer 2014 [Epub ahead of print].
24. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12: 1083-1092.
25. Panzuto F, Merola E, Rinzivillo M et al. Advanced digestive neuroendocrine tumors: Metastatic pattern is an independent factor affecting clinical outcome. Pancreas 2014;43:212-218.
26. Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-565.
27. Yao JC, Lagunes DR, Kulke MH. Targeted therapies in neuroendocrine tumors (NET): Clinical trial challenges and lessons learned. The Oncologist 2013;18:525-532.
28. Ezziddin S, Opitz M, Attassi M et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011;38:459-466.
29. Palazzo M, Lombard-Bohas C, Cadiot G et al. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predictthe antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. Eur J Gastroenterol Hepatol 2013;25:232-238.
30. Sorbye H, Welin S, Langer SW et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013;24:152-160.